[1] Yokosuka O, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol, 2010, 52:791-799.
[2] 夏淑林,张振华,叶珺,等. 恩替卡韦治疗慢性乙型肝炎患者疗效观察. 实用肝脏病杂志, 2011, 14:183-184.
[3] 郝爱芹. 阿德福韦酯联合拉米夫定和单独用恩替卡韦治疗阿德福韦酯耐药的慢性乙型肝炎患者的疗效比较. 新乡医学院学报, 2013, 30:999-1000.
[4] 陈启胜,于文虎,许春仿. 阿德福韦酯联合拉米夫定治疗拉米夫定治疗失效的慢性乙型肝炎疗效分析.实用肝脏病杂志,2012,15:49-50.
[5] Wang PW, Hsieh CJ, Psang LC, et al. Fatty liver and chronic in flammation in Chinese adults. Diabetes Res Clin Pract, 2008, 81:202-208.
[6] 杨襄蓉. 阿德福韦酯治疗慢性乙肝疗效欠佳联合拉米夫定和替比夫定治疗的疗效观察. 现代中西医结合杂志, 2012, 21:1298-1299.
[7] 庄辉, 翁心华. 核苷(酸)类似物抗病毒治疗慢性乙型肝炎的优化策略. 中国病毒病杂志, 2011, 1 :139-142.
[8] Brhl F, Alaei M, Negro F, et al. The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicans. Swiss Med Wkly, 2010, 140:154-159.
[9] 赵攀,韩玉坤,齐冬颖,等. 阿德福韦酯、恩替卡韦单用及拉米夫定联合阿德福韦酯三种方法治疗耐拉米夫定慢性乙肝患者的评价. 实用医院临床杂志, 2011, 8:32-34.
[10] Wang J. Clinical utility of entecavir for chronic hepatitis B in Chinese patients. Drug Des Devel Ther, 2013, 12:13-24.
[11] 杨彦麟,肖萍,高鹏,等. 阿德福韦酯联合拉米夫定治疗慢性乙型肝炎病毒耐药分析. 临床荟萃, 2012, 27 :1852-1855.
[12] 李芳,霞飞飞,李刚,等. 拉米夫定和阿德福韦酯初始联合治疗慢性乙型肝炎的临床研究. 中国医药导报, 2012, 9:85-86.
[13] 李继昌. 替诺福韦治疗重型乙肝临床疗效分析. 海南医学院学报, 2012, 18:1455-1457.
[14] Lee JM, Park JY, Kim do Y, et al. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther, 2010, 15:235-241
[15] 吴杭源,华忠,尤德宏,等. 替比夫定治疗慢性乙型肝炎出现病毒变异联用阿德福韦酯治疗的临床观察. 现代中西医结合杂志, 2011, 20:3791-3793.
[16] Fung J, Lai CL, Yuen MF. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B. Expert Rev Anti Infect Ther, 2010, 8:717-726. |
